Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Griggs, R. C.
Right arrow Articles by Herr, B. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Griggs, R. C.
Right arrow Articles by Herr, B. E.
NEUROLOGY 1983;33:158
© 1983 American Academy of Neurology

The assessment of muscle mass in progressive neuromuscular disease

Robert C. Griggs, MD, Gilbert Forbes, MD, Richard T. Moxley, MD and Barbara Evelyn Herr, BA

Department of Neurology (Drs. Griggs, Moxley, and Ms. Herr), and Department of Pediatrics (Dr. Forbes), University of Rochester School of Medicine and Dentistry, Rochester, NY.

We performed sequential studies of two methods used to estimate muscle mass in 34 patients with progressive neuromuscular disease for periods of up to 52 months. Creatinine excretion and total body potassium were low at the outset in virtually all patients. Creatinine excretion continued to decline in most patients, but total body potassium did not decline significantly. Creatinine excretion may measure declining muscle mass more accurately than total body potassium, but both measurements can estimate muscle mass for metabolic studies or therapeutic trials.

Address correspondence and reprint requests to Dr. Griggs, Department of Neurology, Box 673, University of Rochester, 601 Elmwood Avenue; Rochester, NY 14642.

Supported in part by grants from the Muscular Dystrophy Association, US Public Health Service Grant No. RR 00044 from the Division of Research Resources of the National Institutes of Health, and by a grant from the NIH, National Institute of Arthritis, Metabolism, and Digestive Diseases No. AM 22048; and NICHHD 18-454. A portion of this work was performed under contract number DE-AC02-76EV03490 with the US Department of Energy at the University of Rochester, Department of Radiation, Biology and Biophysics.

Accepted for publication June 18, 1982.




This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
E. Mok, L. Beghin, P. Gachon, C. Daubrosse, J.-E. Fontan, J.-M. Cuisset, F. Gottrand, and R. Hankard
Estimating body composition in children with Duchenne muscular dystrophy: comparison of bioelectrical impedance analysis and skinfold-thickness measurement
Am. J. Clinical Nutrition, January 1, 2006; 83(1): 65 - 69.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P.A. Calabresi, H. Austin, M.K. Racke, A. Goodman, P. Choyke, H. Maloni, and H.F. McFarland
Impaired renal function in progressive multiple sclerosis
Neurology, December 10, 2002; 59(11): 1799 - 1801.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. R. Rose, M. P. McDermott, C. A. Thornton, C. Palenski, W. B. Martens, and R. C. Griggs
A prospective natural history study of inclusion body myositis: Implications for clinical trials
Neurology, August 14, 2001; 57(3): 548 - 550.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K. Bashir and J. N. Whitaker
Clinical and laboratory features of primary progressive and secondary progressive MS
Neurology, September 1, 1999; 53(4): 765 - 765.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
G. M. Fenichel, J. R. Mendell, R. T. Moxley III, R. C. Griggs, M. H. Brooke, J. P. Miller, A. Pestronk, J. Robison, W. King, L. Signore, et al.
A Comparison of Daily and Alternate-Day Prednisone Therapy in the Treatment of Duchenne Muscular Dystrophy
Arch Neurol, June 1, 1991; 48(6): 575 - 579.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
R. C. Griggs, R. T. Moxley III, J. R. Mendell, G. M. Fenichel, M. H. Brooke, A. Pestronk, J. P. Miller, and the Clinical Investigation of Duchenne Dystrophy G
Prednisone in Duchenne Dystrophy: A Randomized, Controlled Trial Defining the Time Course and Dose Response
Arch Neurol, April 1, 1991; 48(4): 383 - 388.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
M. H. Brooke, G. M. Fenichel, R. C. Griggs, J. R. Mendell, R. T. Moxley III, J. P. Miller, K. K. Kaiser, J. M. Florence, S. Pandya, L. Signore, et al.
Clinical Investigation of Duchenne Muscular Dystrophy: Interesting Results in a Trial of Prednisone
Arch Neurol, August 1, 1987; 44(8): 812 - 817.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
R. C. Griggs, W. Kingston, B. E. Herr, G. Forbes, and R. T. Moxley III
Lack of Relationship of Hypogonadism to Muscle Wasting in Myotonic Dystrophy
Arch Neurol, September 1, 1985; 42(9): 881 - 885.
[Abstract] [PDF]

Home page
 Arch NeurolHome page
A. Corbett, W. Kingston, R. C. Griggs, and R. T. Moxley III
Effect of Acetazolamide on Insulin Sensitivity in Myotonic Disorders
Arch Neurol, July 1, 1984; 41(7): 740 - 743.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by AAN Enterprises, Inc.